,
A. J. H. Smith,
,
S. Hunt,|| I. Lavenir, A. Forster, A. J. Warren, G. Grutz,¶ L. Foroni,# M. B. L. Carlton,
W. H. Colledge,
T. Boehm,
and T. H. Rabbitts*
MRC Laboratory of Molecular Biology, Cambridge CB2 2QH, United Kingdom
Received 30 September 2003/ Accepted 9 November 2003
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
or TCR
on chromosome 14q11. In addition, the LMO2 gene is activated in human T-cell acute leukemias via a variant chromosomal translocation, t(7;11)(q35;p13), which breaks at a point near LMO2 on 11p13 and within the T-cell receptor ß TCRß chain gene (35). The final member of this family to be identified was LMO4 (14, 22, 32), which is the most distantly related member of the family. The genes do not exist in tandem, indicating that gene duplication occurred early in the evolution of the family (10, 41). While the LMO1 and LMO2 genes encode proteins that are not closely related (Fig. 1), they are both found on the short arm of human chromosome 11. Conversely, LMO1 and LMO3 genes occur on different chromosomes in humans and mice and encode highly related proteins, especially within the LIM domains (Fig. 1). While LMO1 and LMO2 were discovered because they are activated in distinct human T-cell leukemias by chromosomal translocations, no such association is known for LMO3 or LMO4.
|
The normal role of Lmo2 in development has been established by gene targeting in mice. These studies showed that Lmo2 is a key regulator of hematopoiesis, being necessary both for primitive, yolk sac erythropoiesis in embryos and in definitive hematopoiesis in adults (49, 54). Furthermore, Lmo2 has a controlling function in vascular formation during embryogenesis, as the null mutation of the gene results in failure of the process of endothelial remodeling (angiogenesis) (53). In this way, Lmo2 has features of a master regulator of cell fate, which is a feature thought to be crucial for its role in tumorigenesis following chromosomal translocations (30). Little is known about the function of the other members of the LIM-only family. Lmo1, Lmo3, and Lmo4 are expressed in the developing mouse brain (5, 6, 10, 14, 17, 22, 32, 37, 46, 51) and there is some overlap in the profiles of expression. The related genes Lmo1 and Lmo3 have a different timing of expression in embryonic brain, with Lmo1 being early and Lmo3 being relatively late (5, 10). Neither gene has distinctive expression in hematopoietic tissue. Lmo4, on the other hand, has prolonged expression in brain and is expressed during hematopoiesis (22).
Since Lmo2 has a distinctive role in development, we have studied possible roles of the other members of the LIM-only family by creating null mutations in mice using homologous recombination. Null mutation of Lmo4 results in embryonic lethality, and this mutation can give rise to exencephaly in homozygous null mice. In the case of Lmo1 and Lmo3, null mutation of either gene alone permits production of viable mice, but perinatal death occurs in pups with compound null mutations in both genes. The cause of death could not be identified, but a neural defect seems likely, as expression of these genes is largely restricted to the brain in mouse embryos.
| MATERIALS AND METHODS |
|---|
|
|
|---|
clones were isolated from a 129 library in
2001 (49). Gene targeting into exon 2 of Lmo1 was facilitated by the addition of BamHI adapters to the unique ScaI site and cloning the 1.1-kb pMC1-neopA cassette (55) modified as a BamHI fragment or cloning a 5.1-kb ß-galactosidase reporter comprising an encephalomyocarditis virus (EMC) internal ribosome entry site (IRES) linked to the lacZ gene plus the simian virus 40 polyadenylation site followed by the MC1-neopA sequence (clone p1056). This fragment was cloned as a BamHI fragment into the engineered BamHI site of exon 2. The targeting vector comprised a 5.4-kb EcoRI fragment cloned in pBSpt. Targeted clones were detected using a 3' external probe comprising a 1.5-kb EcoRI-XbaI fragment, which was also used to monitor the transmission of the targeted allele in mice. The Lmo3 targeting strategy employed the introduction of a BamHI site into Lmo3 exon 2 and cloning either pMC1-neopA or the p1056 lacZ reporter. The targeting vector comprised a 6.6-kb BamHI-XhoI fragment cloned in pBSpt. Targeted clones were detected using a 5' external probe comprising a 1-kb BamHI fragment which was also used to monitor the transmission of the targeted allele in mice. The nomenclature of targeted alleles is summarized in Table 1.
|
clones (41). A 9.8-kb XhoI Lmo4 genomic DNA fragment containing exon 1b to exon 4 was isolated from the
phage genomic clone and subcloned into pBluescript. The neomycin resistance gene (neo) was cloned as a 1.1-kb BamHI neo fragment from pMC1-neopA (55) into the blunted EagI site of Lmo4 exon 2, producing a truncated gene which encodes only the first 15 amino acids of Lmo4. The herpes simplex viral thymidine kinase (tk) gene was inserted as a 1.8-kb blunted XbaI fragment from plasmid MC1-tk (38). The Lmo4-GFP knockin clone was made by cloning the hygromycin resistance gene as a 1.7-kb blunted ClaI-BglII fragment from pPGK-hyg (1, 21) containing hyg into the filled-in AflII site of pEGFP-N1 (Clontech) to create pEGFP-hyg. A 2.7-kb blunted BamHI-EcoRV fragment from pEGFP-hyg was inserted into the blunted EagI site of Lmo4 exon 2. The herpes simplex virus tk gene was inserted to allow for negative selection. Gene targeting in ES cells and generation of mutant mice. Embryonic stem (ES) cell lines used were E14 for Lmo1 and Lmo3 or CCB for Lmo4 targeting. Cells were grown on neomycin- or hygromycin-resistant feeders in the presence of leukemia inhibitory factor as described previously (49). DNA transfection was carried out by electroporation, and clones were selected by resistance to G418 (400 µg/ml) or hygromycin (300 µg/ml). Targeted clones were confirmed by filter hybridization and injected in donor blastocysts for generation of chimeric mice. Male chimeras were bred with C57BL/6 females, and germ line transmission was assessed by filter hybridization of tail biopsy specimen DNA. Filter hybridization (36) was carried out as described previously (23). Restriction enzyme-digested DNA was fractionated on 0.8 or 1% agarose and transferred to nylon membranes following denaturation. The filters were hybridized with randomly 32P-labeled DNA probes (9), and specific signal was detected by autoradiography.
Analysis of mice. Anesthetized animals were transcardially perfused with 4% paraformaldehyde (PFA) in phosphate-buffered saline. Brains were removed, postfixed for 15 min in 4% PFA on ice, and equilibrated overnight at 4°C in phosphate-buffered saline-30% sucrose. Sections (40 µm thick) were cut on a sliding microtome and incubated free-floating in X-Gal (5-bromo-4-chloro-3-indolyl-ß-D-galactopyranoside) at 37°C (19). After X-Gal staining, sections were mounted on slides, counterstained with neutral red, and coverslipped with DePeX. RNA analysis was carried out by filter hybridization using glyoxal-treated RNA (39). Total cellular RNA (10 µg per lane) was fractionated on 1.4% agarose and transferred to nylon membranes which were hybridized with randomly 32P-labeled DNA probes (9), and specific signal was detected by autoradiography. Flow cytometry was carried out using antibodies detecting specific hematopoietic lineage markers (purchased from Pharmingen). Mice were screened for populations expressing Sca-1, Mac-1, Gr-1, B220, Thy-1, CD3, CD4, CD8, CD44, and Ter119.
| RESULTS |
|---|
|
|
|---|
|
|
|
|
The compound Lmo1/Lmo3 null mutation affects viability within the first few hours after birth but the cause of death is currently obscure. Histological analysis of major organs including heart, lung, kidney, spleen, thymus, and pancreas showed no obvious difference between compound null mice and controls, and flow cytometric analysis of lineage marker distribution of hematopoietic cells showed no variance for normal patterns (data not shown). As the major expression of Lmo1 and Lmo3 is in developing brain and spinal cord, the anatomy of these structures was examined, but no gross morphological change was observed. The lacZ knockin provided a simple reporter for Lmo1 or Lmo3 expression, and brains taken at P0 from mutant mice were sectioned and subjected to histochemical analysis. All the main structures could be observed in compound Lmo1/Lmo3 null brains. Sections of brains from P0 mice were studied after X-Gal staining, and representatives are shown in Fig. 4 from a (Lmo1-/-; Lmo3Z/Z) null compound. These studies did not reveal any specific differences between null and control brains or any defects to which the cause of death of the compound genotype mice could be attributed.
|
|
12%) lower than the expected Mendelian ratio (Table 4). Therefore, about 50% of Lmo4-/- embryos died after embryonic stage E9.5, and the remaining 50% were born dead.
|
|
The penetrance of this neural tube defect in Lmo4-/- embryos is only about 40 to 50%. Since the Lmo4 gene in the homozygous null animals is interrupted by inserting a neo gene in its exon 2, which encodes the first LIM domain, it could be possible that an alternative splicing variant of the Lmo4 transcript consisting of the 5' untranslated region and exons 3, 4, and 5 is formed (41). This splicing variant, if formed and translated, would contain the second LIM domain of the protein, which might be sufficient for a degree of function. RNA filter hybridization (Fig. 7) was used to check if the nonexencephalic Lmo4-/- embryos have such a splicing variant of Lmo4. Total RNA was isolated from wild-type, Lmo4+/-, exencephalic Lmo4-/-, or nonexencephalic Lmo4-/- whole embryos and assayed by filter hybridization using a probe containing Lmo4 cDNA sequences 3' to the neo insertion site. By contrast to the wild-type and Lmo4+/- embryos, both Lmo4-/- embryos had no detectable Lmo4 transcript, suggesting that no alternative Lmo4 splicing variant occurs in the nonexencephalic Lmo4-/- embryo (Fig. 5).
|
Intact hematopoiesis in Lmo4 mutant mice. Various internal organs were taken from E18.5 Lmo4-/- and wild-type embryos for histological analyses. Microscopic examination of tissue sections of skin, heart, lung, liver, spleen, thymus, and kidney of the Lmo4-/- embryos showed no abnormalities. As mouse spleen at embryonic stage E18.5 is still a major hematopoietic organ and Lmo4-/- mice die at birth, examination of spleen at E18.5 was used to determine if hematopoiesis in Lmo4-/- embryos is grossly intact. Cells at different stages of maturation were seen for both erythroid and myeloid lineages. Lymphocytes and megakaryocytes were also present. Therefore, no obvious hematopoietic anomaly was found in Lmo4-/- embryos. Histological sections of the thymus were also examined, and no marked difference in cellularity was observed between the thymus of Lmo4-/- embryos and that of the wild-type mice, and the cortex-medulla demarcation and the general architecture of the Lmo4-/- thymus were well preserved. Fluorescence-activated cell sorter analysis of the lymphocytes from E18.5 Lmo4-/- embryos did not reveal any abnormalities. To ensure that normal T- and B-cell development could occur in adult mice, we examined ES-cell-derived lymphopoiesis in Rag1 null mice, which lack the ability to develop mature lymphocytes (25). Injecting Lmo4-/Lmo4-/- null ES cells into Rag1 null blastocysts and using GFP as a marker of Lmo4 expression resulted in adult mice with a normal lymphocyte differentiation pattern derived from ES cells, indicating that lymphopoiesis is not altered by the Lmo4 null mutation (W. Swat and F. W. Alt, data not shown).
| DISCUSSION |
|---|
|
|
|---|
|
Complementary and noncomplementary functions of Lmo1, Lmo3, and Lmo4 genes in central nervous system development. The expression of Lmo1 and Lmo3 is highly restricted and is largely found in the developing nervous system and, in the case of Lmo3, persists in adult brain and spinal cord (5, 10, 12, 17). Lmo4 has more-widespread expression (6, 14, 22, 32, 46). The consequence of creating a null mutation in the Lmo4 gene is more profound than that of creating a null mutation in either Lmo1 or Lmo3, as a high incidence of neural tube closure failure is found in Lmo4 null mice. While the Lmo1-Lmo3 compound null mice die soon after birth, no obvious cause of death could be determined. As Lmo3 expression seems restricted to neural tissue, at least through embryogenesis, the defect must presumably occur in neural tissue itself. The complementary profiles of Lmo1 and Lmo3 gene expression and the overlapping timing of expression suggest that Lmo3 fulfills the role of Lmo1 in Lmo1 null mice, which facilitates the viability of these animals. The high sequence similarity in the derived Lmo1 and Lmo3 proteins, especially in the LIM domains (Fig. 1), makes such a molecular complementation seem possible. In compound Lmo1-Lmo3 null mice, loss of both genes results in a lethal phenotype, and therefore complementarity is restricted to the two related genes.
The LIM-only proteins are developmental regulators. A normal role for each member of the LIM-only family in development is now established (Table 5). Lmo2 is an essential regulator of primitive and definitive hematopoiesis as well as angiogenesis (52-54). The Lmo2 role in hematopoiesis appears unique among the LIM-only proteins, as null mutation of the other three members does not visibly affect the differentiation and distribution of cell types in the hematopoietic compartment, although a role in the function of individual cell types cannot be ruled out. Rather, the Lmo1, Lmo3, and Lmo4 genes are implicated in the control of neural development. In each case, the absence of the gene results in perinatal lethality, with a discernible phenotype in the case of Lmo4 null mutations, i.e., exencephaly or an inferred neural defect in the case of Lmo1 plus Lmo3 mutations.
These developmental regulators can be involved in cancer pathogenesis. Two of the members, LMO1 and LMO2, are involved in distinct T-cell leukemias by association with chromosomal translocation breakpoints (29) but neither LMO3 nor LMO4 has been found at chromosomal translocation breakpoints. However, LMO4 was first recognized as an auto-antigen in breast tumors (32), where it is overexpressed and has a function in differentiation of mammary epithelium (45, 51). The subversion of developmental regulators after chromosomal translocations have occurred in somatic cells has been highlighted as the principle consequence of such abnormal chromosomes in acute leukemias and sarcomas, and the aberrant use of these and other transcription factors in cancer is likely to be a common feature.
| ACKNOWLEDGMENTS |
|---|
We are indebted to W. Swat and F. W. Alt (Howard Hughes Medical Institute, Children's Hospital, Boston, Mass.) for conducting the Rag complementation experiments.
| FOOTNOTES |
|---|
E.T. and A.J.H.S. made equal contributions. ![]()
Present address: Division of Haematology and Oncology, Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong. ![]()
Present address: Centre for Genome Research, University of Edinburgh, Edinburgh EH9 3JQ, United Kingdom. ![]()
¶ Present address: Institute for Medical Immunology, Medical School Charité, D-10117 Berlin, Germany. ![]()
|| Present address: Department of Anatomy and Developmental Biology, University College, London WC1E 6BT, United Kingdom. ![]()
# Present address: Department of Haematology, Royal Free Hospital, London NW3 2QG, United Kingdom. ![]()

Present address: CRC-Wellcome Institute, Cambridge CB2 3EG, United Kingdom. ![]()

Present address: Physiological Laboratory, University of Cambridge, Cambridge CB2 3EG, United Kingdom. ![]()

Present address: Department of Developmental Immunology, Max-Planck-Institut für Immunbiologie, Freiburg D-79108, Germany. ![]()
| REFERENCES |
|---|
|
|
|---|
2. Boehm, T., R. Baer, I. Lavenir, A. Forster, J. J. Waters, E. Nacheva, and T. H. Rabbitts. 1988. The mechanism of chromosomal translocation t(11;14) involving the T-cell receptor C
locus on human chromosome 14q11 and a transcribed region of chromosome 11p15. EMBO J. 7:385-394.[Medline]
3. Boehm, T., L. Foroni, Y. Kaneko, M. P. Perutz, and T. H. Rabbitts. 1991. The rhombotin family of cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13. Proc. Natl. Acad. Sci. USA 88:4367-4371.
4. Boehm, T., L. Foroni, M. Kennedy, and T. H. Rabbitts. 1990. The rhombotin gene belongs to a class of transcriptional regulators with a potential novel protein dimerisation motif. Oncogene 5:1103-1105.[Medline]
5. Boehm, T., M.-G. Spillantini, M. V. Sofroniew, M. A. Surani, and T. H. Rabbitts. 1991. Developmentally regulated and tissue-specific expression of mRNAs encoding the two alternative forms of the LIM domain oncogene rhombotin: evidence for thymus expression. Oncogene 6:695-703.[Medline]
6. Chen, H. H., J. W. Yip, A. F. Stewart, and E. Frank. 2002. Differential expression of a transcription regulatory factor, the LIM domain only 4 protein Lmo4, in muscle sensory neurons. Development 129:4879-4889.
7. Copp, A. J., F. A. Brook, J. P. Estibeiro, A. S. Shum, and D. L. Cockcroft. 1990. The embryonic development of mammalian neural tube defects. Prog. Neurobiol. 35:363-403.[CrossRef][Medline]
8. Epstein, D. J., M. Vekemans, and P. Gros. 1991. splotch (Sp2H), a mutation affecting development of mouse neural tube, shows a deletion within the paired homeodomain of Pax-3. Cell 67:767-774.[CrossRef][Medline]
9. Feinberg, A. P., and B. A. Vogelstein. 1983. A technique for radiolabelling DNA restriction endonuclease fragments to high specific activity. Anal. Biochem. 132:6-13.[CrossRef][Medline]
10. Foroni, L., T. Boehm, L. White, A. Forster, P. Sherrington, X. B. Liao, C. I. Brannan, N. A. Jenkins, N. G. Copeland, and T. H. Rabbitts. 1992. The rhombotin gene family encode related LIM-domain proteins whose differing expression suggests multiple roles in mouse development. J. Mol. Biol. 226:747-761.[CrossRef][Medline]
11. Freyd, G., S. K. Kim, and H. R. Horvitz. 1990. Novel cysteine-rich motif and homeodomain in the product of the Caenorhabditis elegans cell lineage gene lin-11. Nature 344:876-879.[CrossRef][Medline]
12. Greenberg, J. M., T. Boehm, M. V. Sofroniew, R. J. Keynes, S. C. Barton, M. L. Norris, M. A. Surani, M.-G. Spillantini, and T. H. Rabbitts. 1990. Segmental and developmental regulation of a presumptive T-cell oncogene in the central nervous system. Nature 344:158-160.[CrossRef][Medline]
13. Grutz, G., K. Bucher, I. Lavenir, R. Larson, T. Larson, and T. H. Rabbitts. 1998. The oncogenic T cell LIM-protein Lmo2 forms part of a DNA-binding complex specifically in immature T cells. EMBO J. 17:4594-4605.[CrossRef][Medline]
14. Grutz, G., A. Forster, and T. H. Rabbitts. 1998. Identification of the LMO4 gene encoding an interaction partner of the LIM-binding protein LDB1/NLI1: a candidate for displacement by LMO proteins in T cell acute leukaemia. Oncogene 17:2799-2803.[CrossRef][Medline]
15. Harris, M. J., and D. M. Juriloff. 1999. Mini-review: toward understanding mechanisms of genetic neural tube defects in mice. Teratology 60:292-305.[CrossRef][Medline]
16. Hermanson, O., T. M. Sugihara, and B. Andersen. 1999. Expression of LMO-4 in the central nervous system of the embryonic and adult mouse. Cell. Mol. Biol. (Noisy-Le-Grand) 45:677-686.
17. Hinks, G. L., B. Shah, S. J. French, L. S. Campos, K. Staley, J. Hughes, and M. V. Sofroniew. 1997. Expression of LIM protein genes Lmo1, Lmo2, and Lmo3 in adult mouse hippocampus and other forebrain regions: differential regulation by seizure activity. J. Neurosci. 17:5549-5559.
18. Hollander, M. C., M. S. Sheikh, D. V. Bulavin, K. Lundgren, L. Augeri-Henmueller, R. Shehee, T. A. Molinaro, K. E. Kim, E. Tolosa, J. D. Ashwell, M. P. Rosenberg, Q. Zhan, P. M. Fernandez-Salguero, W. F. Morgan, C. X. Deng, and A. J. Fornace, Jr. 1999. Genomic instability in Gadd45a-deficient mice. Nat. Genet. 23:176-184.[CrossRef][Medline]
19. Jones, A., S. Bahn, A. L. Grant, M. Kohler, and W. Wisden. 1996. Characterization of a cerebellar granule cell-specific gene encoding the gamma-aminobutyric acid type A receptor alpha 6 subunit. J. Neurochem. 67:907-916.[Medline]
20. Karlsson, O., S. Thor, T. Norberg, H. Ohlsson, and T. Edlund. 1990. Insulin gene enhancer binding protein Isl-1 is a member of a novel class of proteins containing both a homeo- and a cys-his domain. Nature 344:879-882.[CrossRef][Medline]
21. Kaster, K. R., S. G. Burgett, R. N. Rao, and T. D. Ingolia. 1983. Analysis of a bacterial hygromycin B resistance gene by transcriptional and translational fusions and by DNA sequencing. Nucleic Acids Res. 11:6895-6911.
22. Kenny, D. A., L. W. Jurata, Y. Saga, and G. N. Gill. 1998. Identification and characterization of LMO4, an LMO gene with a novel pattern of expression during embryogenesis. Proc. Natl. Acad. Sci. USA 95:11257-11262.
23. LeFranc, M.-P., A. Forster, R. Baer, M. A. Stinson, and T. H. Rabbitts. 1986. Diversity and rearrangement of the human T cell rearranging
genes: nine germ-line variable genes belonging to two subgroups. Cell 45:237-246.[CrossRef][Medline]
24. McGuire, E. A., R. D. Hockett, K. M. Pollock, M. F. Bartholdi, S. J. O'Brien, and S. J. Korsmeyer. 1989. The t(11;14)(p15;q11) in a T-cell acute lymphoblastic leukemia cell line activates multiple transcripts, including Ttg-1, a gene encoding a potential zinc finger protein. Mol. Cell. Biol. 9:2124-2132.
25. Mombaerts, P., J. Iacomini, R. S. Johnson, K. Herrup, S. Tonegawa, and V. E. Papaioannou. 1992. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68:869-877.[CrossRef][Medline]
26. Neumann, P. E., W. N. Frankel, V. A. Letts, J. M. Coffin, A. J. Copp, and M. Bernfield. 1994. Multifactorial inheritance of neural tube defects: localization of the major gene and recognition of modifiers in ct mutant mice. Nat. Genet. 6:357-362.[CrossRef][Medline]
27. Osada, H., G. Grutz, H. Axelson, A. Forster, and T. H. Rabbitts. 1995. Association of erythroid transcription factors: complexes involving the LIM protein RBTN2 and the zinc-finger protein GATA1. Proc. Natl. Acad. Sci. USA 92:9585-9589.
28. Perez-Alvarado, G. C., C. Miles, J. W. Michelsen, H. A. Louis, D. R. Winge, M. C. Beckerle, and M. F. Summers. 1994. Structure of the carboxy-terminal LIM domain from the cysteine rich protein CRP. Nat. Struct. Biol. 1:388-398.[CrossRef][Medline]
29. Rabbitts, T. H. 1998. LMO T-cell translocation oncogenes typify genes activated by chromosomal translocations that alter transcription and developmental processes. Genes Dev. 12:2651-2657.
30. Rabbitts, T. H. 1991. Translocations, master genes, and differences between the origins of acute and chronic leukemias. Cell 67:641-644.[CrossRef][Medline]
31. Rabbitts, T. H., and T. Boehm. 1990. LIM domains. Nature 346:418.[Medline]
32. Racevskis, J., A. Dill, J. A. Sparano, and H. Ruan. 1999. Molecular cloning of LMO4, a new human LIM domain gene. Biochim. Biophys. Acta 1445:148-153.[Medline]
33. Royer-Pokora, B., U. Loos, and W.-D. Ludwig. 1991. TTG-2, a new gene encoding a cysteine-rich protein with the LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14)(p13;q11). Oncogene 6:1887-1893.[Medline]
34. Sah, V. P., L. D. Attardi, G. J. Mulligan, B. O. Williams, R. T. Bronson, and T. Jacks. 1995. A subset of p53-deficient embryos exhibit exencephaly. Nat. Genet. 10:175-180.[CrossRef][Medline]
35. Sanchez-Garcia, I., Y. Kaneko, R. Gonzalez-Sarmiento, K. Campbell, L. White, T. Boehm, and T. H. Rabbitts. 1991. A study of chromosome 11p13 translocations involving TCRß and TCR
in human T cell leukaemia. Oncogene 6:577-582.[Medline]
36. Southern, E. M. 1975. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J. Mol. Biol. 98:503-517.[CrossRef][Medline]
37. Sugihara, T. M., I. Bach, C. Kioussi, M. G. Rosenfeld, and B. Andersen. 1998. Mouse deformed epidermal autoregulatory factor 1 recruits a LIM domain factor, LMO-4, and CLIM coregulators. Proc. Natl. Acad. Sci. USA 95:15418-15423.
38. Thomas, K. R., and M. R. Capecchi. 1987. Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell 51:503-512.[CrossRef][Medline]
39. Thomas, P. S. 1980. Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose. Proc. Natl. Acad. Sci. USA 77:5201-5205.
40. Tozawa, R., S. Ishibashi, J. Osuga, H. Yagyu, T. Oka, Z. Chen, K. Ohashi, S. Perrey, F. Shionoiri, N. Yahagi, K. Harada, T. Gotoda, Y. Yazaki, and N. Yamada. 1999. Embryonic lethality and defective neural tube closure in mice lacking squalene synthase. J. Biol. Chem. 274:30843-30848.
41. Tse, E., G. Grutz, A. A. Garner, Y. Ramsey, N. P. Carter, N. Copeland, D. J. Gilbert, N. A. Jenkins, A. Agulnick, A. Forster, and T. H. Rabbitts. 1999. Characterisation of the Lmo4 gene encoding a LIM-only protein: genomic organisation and comparative chromosomal mapping. Mamm. Genome 10:1089-1094.[CrossRef][Medline]
42. Valge-Archer, V., A. Forster, and T. H. Rabbitts. 1998. The LMO1 and LDB1 proteins interact in human T cell acute leukaemia with the chromosomal translocation t(11;14)(p15;q11). Oncogene 17:3199-3202.[CrossRef][Medline]
43. Valge-Archer, V. E., H. Osada, A. J. Warren, A. Forster, J. Li, R. Baer, and T. H. Rabbitts. 1994. The LIM protein RBTN2 and the bHLH protein TAL1 are present in a complex in erythroid cells. Proc. Natl. Acad. Sci. USA 91:8617-8621.
44. Visvader, J. E., X. Mao, Y. Fujiwara, K. Hahm, and S. H. Orkin. 1997. The LIM-domain binding protein Ldb1 and its partner LMO2 act as negative regulators of erythroid differentiation. Proc. Natl. Acad. Sci. USA 94:13707-13712.
45. Visvader, J. E., D. Venter, K. Hahm, M. Santamaria, E. Y. Sum, L. O'Reilly, D. White, R. Williams, J. Armes, and G. J. Lindeman. 2001. The LIM domain gene LMO4 inhibits differentiation of mammary epithelial cells in vitro and is overexpressed in breast cancer. Proc. Natl. Acad. Sci. USA 98:14452-14457.
46. Vu, D., P. Marin, C. Walzer, M. M. Cathieni, E. N. Bianchi, F. Saidji, G. Leuba, C. Bouras, and A. Savioz. 2003. Transcription regulator LMO4 interferes with neuritogenesis in human SH-SY5Y neuroblastoma cells. Brain Res. Mol. Brain Res. 115:93-103.[Medline]
47. Wadman, I., J. Li, R. O. Bash, A. Forster, H. Osada, T. H. Rabbitts, and R. Baer. 1994. Specific in vivo association between the bHLH and LIM proteins implicated in human T cell leukaemia. EMBO J. 13:4831-4839.[Medline]
48. Wadman, I. A., H. Osada, G. G. Grutz, A. D. Agulnick, H. Westphal, A. Forster, and T. H. Rabbitts. 1997. The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins. EMBO J. 16:3145-3157.[CrossRef][Medline]
49. Warren, A. J., W. H. Colledge, M. B. L. Carlton, M. J. Evans, A. J. H. Smith, and T. H. Rabbitts. 1994. The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid development. Cell 78:45-58.[CrossRef][Medline]
50. Way, J. C., and M. Chalfie. 1988. mec-3, a homeobox-containing gene that specifies differentiation of the touch receptor neurons in C. elegans. Cell 54:5-16.[CrossRef][Medline]
51. Wittlin, S., E. Y. Sum, N. K. Jonas, G. J. Lindeman, and J. E. Visvader. 2003. Two promoters within the human LMO4 gene contribute to its overexpression in breast cancer cells. Genomics 82:280-287.[CrossRef][Medline]
52. Yamada, Y., R. Pannell, A. Forster, and T. H. Rabbitts. 2002. The LIM-domain protein Lmo2 is a key regulator of tumour anogiogenesis: a new anti-angiogenesis drug target. Oncogene 21:1309-1315.[CrossRef][Medline]
53. Yamada, Y., R. Pannell, A. Forster, and T. H. Rabbitts. 2000. The oncogenic LIM-only transcription factor Lmo2 regulates angiogenesis but not vasculogenesis. Proc. Natl. Acad. Sci. USA 97:320-324.
54. Yamada, Y., A. W. Warren, C. Dobson, A. Forster, R. Pannell, and T. H. Rabbitts. 1998. The T cell leukaemia LIM protein Lmo2 is necessary for adult mouse haematopoiesis. Proc. Natl. Acad. Sci. USA 95:3890-3895.
55. Yenofsky, R. L., M. Fine, and J. W. Pellow. 1990. A mutant neomycin phosphotransferase II gene reduces the resistance of transformants to antibiotic selection pressure. Proc. Natl. Acad. Sci. USA 87:3435-3439.
56. Ziller, C., M. Fauquet, C. Kalcheim, J. Smith, and N. M. Le Douarin. 1987. Cell lineages in peripheral nervous system ontogeny: medium-induced modulation of neuronal phenotypic expression in neural crest cell cultures. Dev. Biol. 120:101-111.[CrossRef][Medline]
This article has been cited by other articles:
| ||||||||||||||||||||||||||||||||